My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about PGNS

    THE HAGUE, Netherlands, June 14 /PRNewswire/ -- Two-year data on TOBI(R)
 (tobramycin solution for inhalation), which is marketed by PathoGenesis Corp.
 (Nasdaq:   PGNS), were presented at a satellite meeting of the 23rd European
 Cystic Fibrosis Conference.
     "The two-year adolescent data are particularly exciting, because the
 results suggest that TOBI can modify the course of the disease," said
 C. Michael Bowman, Ph.D., M.D., of the University of Southern California
 Department of Pediatrics, Los Angeles, who presented the data at the European
 conference.  "The data show that chronic intermittent therapy with TOBI
 maintains benefits to patients for at least 96 weeks."
     Patients inhaling TOBI in repeated cycles of 28 days on drug, 28 days off
 drug were treated for up to two years.  At the end of the last on-drug period,
 these patients had on average a 4.8 percent relative improvement in lung
 function above the baseline.  Although this treatment experience was open
 label, other studies and statistics generally have shown an annual relative
 lung function decline of 2 percent to 7 percent in comparable cystic fibrosis
 patients receiving standard therapies, or about 4 percent to 14 percent over
 two years.  While TOBI therapy resulted in treatment benefits for all age
 groups, patients who were 13 to 17 years old demonstrated a larger treatment
 effect of 14.3 percent in relative lung function improvement above the
 baseline after two years.
     "The two-year data confirms what we've been hearing from cystic fibrosis
 patients," said Wilbur H. Gantz, chairman and chief executive officer of
 PathoGenesis.  "TOBI works and it works well."
     Additional data from the two-year study of TOBI will be presented at the
 North American Cystic Fibrosis Conference, Oct. 7-10 in Seattle.
     Each ready-to-use ampule of TOBI contains 300 milligrams of tobramycin in
 a 5 milliliter solution.  TOBI is aerosolized and administered using a PARI LC
 PLUS(TM) reusable nebulizer and a DeVilbiss Pulmo-Aide(R) air compressor.  It
 is inhaled twice daily and requires about 15 minutes per treatment.  The TOBI
 treatment regimen consists of repeated cycles of 28 days on drug, followed by
 28 days off drug.
     Seattle-based PathoGenesis Corp. is a pharmaceutical company that develops
 drugs to treat chronic infectious diseases -- lung infections, in particular
 -- where there is a significant need for improved therapy.  The company
 markets TOBI, an inhaled antibiotic, in the U.S., Canada, and Argentina for
 management of P. aeruginosa infections in patients with cystic fibrosis.
 Applications for regulatory approval of TOBI have been filed in Europe and
 other markets.  In addition, PathoGenesis is further developing TOBI and other
 drug candidates to treat serious chronic lung infections, including those
 common in cystic fibrosis, bronchiectasis and tuberculosis patients.
 PathoGenesis' stock is traded on the Nasdaq National Market System under the
 symbol PGNS.  The company's Web site is located at www.pathogenesis.com .
     Note:  This news release contains "forward-looking statements" within the
 meaning of the Private Securities Litigation Reform Act of 1995.  Such
 forward-looking statements are subject to known and unknown risks,
 uncertainties or other factors that may cause the company's actual results to
 be materially different from historical results or any results expressed or
 implied by such forward-looking statements.  Factors that might cause such a
 difference include, but are not limited to, uncertainties related to the fact
 that PathoGenesis only began commercial operations in 1998, its dependence on
 TOBI, the degree of penetration of its markets and frequency of TOBI's use by
 patients, third party reimbursement and product pricing, seasonal impacts on
 hospitalizations or exacerbations experienced by cystic fibrosis patients,
 variability in wholesaler ordering patterns, drug development and clinical
 trials, competition and alternative therapies, and other factors described in
 PathoGenesis' filings with the Securities and Exchange Commission, including
 the company's Form 10-K for 1998 and Exhibit 99.1 to that Form 10-K.
 
 

SOURCE  PathoGenesis Corporation